Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293773 | 1.00 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3293769 | 1.00 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3287453 | 1.00 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3292412 | 0.92 | CA2 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3292415 | 0.92 | CA2 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3292424 | 0.92 | CA2 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3287358 | 0.91 | NPC1 (0.44) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL3287355 | 0.91 | NPC1 (0.44) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL3287363 | 0.91 | NPC1 (0.44) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL3293133 | 0.90 | FLT1 (0.53) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | claimed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | claimed |
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | AR, ADRA2A, ADRA1A | CA1 3991/4885CA2 2746/4885CA7 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.